

13. (New) A method for treating an animal, including a human, having an apicomplex parasite, comprising administering the pharmaceutical composition claimed in claim 12 to said animal.

14. (New) The method as claimed in Claim 13, wherein the apicomplex parasite is selected from the group consisting of *Plasmodium*, *Toxoplasma* and *Eimeria*.

15. (New) A pharmaceutical composition comprising an MGDG synthase inhibitor and a pharmaceutically-acceptable carrier or excipient, wherein said MGDG synthase inhibitor is selected by the method claimed in claim 4.

16. (New) An herbicide comprising an MGDG synthase inhibitor and a carrier, wherein said MGDG synthase inhibitor is selected by the method claimed in claim 4.

17. (New) A method comprising treating a plant with the herbicide claimed in claim 16, comprising applying said herbicide to a plant.--

REMARKS

Claims 4-9 and 12-17 are active in the present application. Claims 1-3 and 10-11 have been cancelled. Claims 12-17 are new claims. Support for the new claims is found in the original claims. Claims 4-9 have been amended to remove multiple dependencies and for clarity. By virtue of the present amendment, a fee is not required for multiple dependent claims.

No new matter is added by the present amendment.

Applicants have now submitted an substitute Sequence Listing and a corresponding computer-readable Sequence Listing. The sequence information recorded in the corresponding computer-readable Sequence Listing is identical to the paper copy of the substitute Sequence Listing. Support for all of the sequences listed in the substitute Sequence Listing is found in the present application as originally filed. No new matter is

believed to have been introduced by the submission of the substitute Sequence Listing and the corresponding computer-readable Sequence Listing.

Applicants submit that the present application is ready for examination on the merits. Early notice to this effect is earnestly solicited.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.



Norman F. Oblon
Attorney of Record
Registration No. 24,618

Vincent K. Shier, Ph.D.
Registration No. 50,552

Tel: 703-413-3000
Fax: 703-413-2220
NFO:VKS:kh
I:\atty\VKS\213993US-Prel Amend.wpd



22850

44

MARKED-UP COPY

IN THE SPECIFICATION

Please replace the paragraph starting on page 6, line 28 with the following:

- figure 2 is a comparison of spinach, cucumber and Arabidopsis MGDG synthase; figure 2A corresponds to a comparison of the amino acid sequences deduced from the cDNAs encoding the various MGDG synthases; in this figure, atMGD A (SEQ ID No. 10) and atMGD B (SEQ ID No. 11) correspond to sequences derived from *Arabidopsis thaliana*, csMGD A (SEQ ID No. 9) corresponds to a sequence derived from *Cucumis sativa* and soMGD A (SEQ ID No. 8) corresponds to a sequence derived from *Spinacia oleracea*. * and : represent symbols for the identical amino acids and the conserved substitutions, respectively; h1 to h7 correspond to 7 putative α -helices; figure 2B represents a phylogenic tree of mature MGDG synthases;

IN THE CLAIMS

Please amend the claims as follows:

--Claims 1-3 and 10-11 (Cancelled).--

--4. (Amended) A method for screening and for selecting antiparasitic agents, [and/or] herbicides or combinations thereof, [characterized in that it comprises:] comprising,

-incubating a substance to be tested with an MGDG synthase or with a plastidial membrane isolated from a plant, and

-measuring the specific enzymatic activity, after said incubation.

5. (Amended) The method as claimed in claim 4, [characterized in that] wherein said MGDG synthase [preferably] has an initial specific activity of between 0.1 and 120 μ mol of galactose incorporated/h/mg of protein.

6. (Amended) The method as claimed in claim 4 [or claim 5 characterized in that] , wherein the MGDG synthase/substance to be tested incubation is carried out in an incubation medium containing a buffer adjusted to a pH of between 6 and 9, in the presence of detergents, [of] a reducing agent, [of] phosphatidylglycerol, [and of] a salt or combinations thereof.

7. (Amended) The method as claimed in claim 6, [characterized in that] wherein the incubation medium [preferably contains] further comprises 50 mM of MOPS-NaOH, [pH 7.8,] 4.5 mM of CHAPS, 1 mM of DTT, 1.3 mM of phosphatidylglycerol, 250 mM of $\text{KH}_2\text{PO}_4/\text{K}_2\text{HPO}_4$ and 250 mM of KCl, and has a pH of 7.8.

8. (Amended) The method according to [any one of claims 4 to 7, characterized in that] claim 4, wherein the MGDG synthase is of plant origin and is selected from the group consisting of the purified [or recombinant] MGDG synthases A, recombinant MGDG synthases A, purified MGDG synthases B, and recombinant [and] MGDG synthases B.

9. (Amended) The method as claimed in [any one of claims 4 to 8, characterized in that] claim 4, wherein said apicomplex parasite is selected from the group consisting of *Plasmodium*, *Toxoplasma* and *Eimeria*.--

--Claims 12-15 (New).--

